Edition:
United States

Myriad Genetics Inc (MYGN.OQ)

MYGN.OQ on NASDAQ Stock Exchange Global Select Market

17.61USD
21 Apr 2017
Change (% chg)

$-0.14 (-0.79%)
Prev Close
$17.75
Open
$17.75
Day's High
$17.84
Day's Low
$17.55
Volume
228,295
Avg. Vol
516,927
52-wk High
$38.03
52-wk Low
$15.15

Latest Key Developments (Source: Significant Developments)

Myriad Genetics, Beigene sign agreement
Thursday, 6 Apr 2017 07:05am EDT 

Myriad Genetics Inc : Myriad Genetics and Beigene sign agreement to develop companion diagnostics for use with Beigene's novel parp inhibitor, BGB-290 . Myriad Genetics Inc - specific terms of deal were not disclosed. .Myriad Genetics-under deal Beigene to use co's mychoice HRD, bracanalysis CDX companion diagnostic tests to support clinical development of BGB-290.  Full Article

Myriad Genetics publishes study evaluating its myPath melanoma test
Wednesday, 5 Apr 2017 07:05am EDT 

Myriad Genetics Inc - : Myriad Genetics -published third clinical validation study and second clinical utility study for its mypath melanoma test . Myriad Genetics Inc says will submit reimbursement dossier to medicare and private insurers three months earlier than expected .Myriad Genetics-3rd clinical validation study shows mypath melanoma test had overall diagnostic accuracy of 95 percent to differentiate melanoma from benign lesions.  Full Article

Myriad Genetics director Henderson buys 6,000 shares of co's common stock on Feb 22-23
Thursday, 23 Feb 2017 11:27am EST 

Myriad Genetics Inc :Myriad Genetics Inc director John Henderson reports purchase of 6,000 shares of co's common stock on Feb 22-23 - SEC filing.  Full Article

Myriad Genetics reports fiscal Q2 2017 financial results
Tuesday, 7 Feb 2017 04:05pm EST 

Myriad Genetics Inc : Myriad Genetics reports fiscal second-quarter 2017 financial results . Q2 adjusted earnings per share $0.26 . Q2 GAAP earnings per share $0.09 . Q2 revenue $196.5 million versus I/B/E/S view $189.7 million . Q2 earnings per share view $0.24 -- Thomson Reuters I/B/E/S . Myriad Genetics Inc sees FY 2017 GAAP revenue $745-$755 million . Myriad Genetics Inc sees FY 2017 GAAP diluted earnings per share $0.31-$0.36 . Myriad Genetics Inc sees FY 2017 adjusted earnings per share $1.00-$1.05 . Myriad Genetics Inc sees Q3 revenue $188-$190 million . Myriad Genetics Inc sees Q3 GAAP diluted earnings per share $0.08-$0.10 . Myriad Genetics Inc sees Q3 adjusted earnings per share $0.23-$0.25 . Q3 earnings per share view $0.25, revenue view $190.2 million -- Thomson Reuters I/B/E/S .FY2017 earnings per share view $0.98, revenue view $751.8 million -- Thomson Reuters I/B/E/S.  Full Article

Myriad Genetics says entered into credit agreement for $300 mln on Dec.23-SEC filing
Wednesday, 28 Dec 2016 11:51am EST 

Myriad Genetics Inc : On Dec. 23, 2016, entered into a credit agreement - SEC filing . Senior secured revolving credit facility in an aggregate principal amount of up to $300 mln-SEC filing .Credit facility matures on Dec. 23, 2021.  Full Article

Myriad RBM announces agreement with Sanofi
Tuesday, 25 Oct 2016 07:05am EDT 

Myriad Genetics Inc : Announces an agreement with Sanofi to measure predictive cardiovascular biomarkers in patients with diabetes . Financial terms of deal were not disclosed .Under agreement, Sanofi will provide approximately 5,300 serum samples from elixa trial.  Full Article

Myriad Genetics to enter into a credit agreement
Thursday, 1 Sep 2016 04:25pm EDT 

Myriad Genetics Inc : Says on August 31 co entered into a credit agreement . Pursuant to credit agreement, Myriad borrowed term loans in an aggregate principal amount of $200.0 million .Proceeds of term loans used to finance acquisition of Assurex ,refinance certain existing indebtedness of Assurex and its units.  Full Article

Myriad Genetics reports Q4 earnings per share $0.32
Tuesday, 9 Aug 2016 04:05pm EDT 

Myriad Genetics : Reports fiscal fourth-quarter 2016 financial results . Q4 earnings per share $0.32 . Q4 earnings per share view $0.37 -- Thomson Reuters I/B/E/S . Q4 adjusted earnings per share $0.36 .Q4 revenue $186.5 million versus I/B/E/S view $187.9 million.  Full Article

Myriad Genetics board approves additional $200 mln share repurchase program
Tuesday, 7 Jun 2016 07:05am EDT 

Myriad Genetics Inc : Myriad board approves $200 million increase in share repurchase program .Approved an additional $200 million authorization for its share repurchase program.  Full Article

Myriad acquires Sividon Diagnostics for 35 mln euros
Tuesday, 31 May 2016 04:05pm EDT 

Myriad Genetics Inc : Myriad acquires Sividon Diagnostics . Has acquired Sividon Diagnostics for eur 35 million upfront with potential for eur 15 million in additional performance-based milestones .Myriad expects deal to be neutral to both revenue and earnings in fiscal year 2017.  Full Article

More From Around the Web

BRIEF-Myriad Genetics, Beigene sign agreement

* Myriad Genetics and Beigene sign agreement to develop companion diagnostics for use with Beigene's novel parp inhibitor, BGB-290